I think that Dr J becoming longterm CEO is unrealistic. He also is doing it for min salary right now, another benefit to investors. If you listened to the whole call he is juggling running quest amongst other things. I think he is playing a major short term role to get leronlimab in a fair trial in which it can best show efficiency. Help get data published in journals and to find best possible partnerships/buy out to advance other indications. I wouldn’t anticipate him taking up the CEO role longterm. It would be possibly more beneficial for him to be a consultant for cydy or on the board which he could more likely have a balance between his other obligations. Just my thoughts as already know when the day comes that he is no longer interim CEO the basher group will say he is abandoning and sinking ship the sky is falling etc…One positive that has come out of the past couple years is that leronlimab once again proven safety record for all indications there have been any Clinical data and when it competes in any indication in the future likely have least side effects by far. Really interesting as to how big CYDY could be after first approval of anything since off label sales could be the biggest thing ever. Look at Humara as good example or look at the relatively new diabetes drug Ozempic was approved for diabetes how ever change the name and tens of thousands more taking it for weight loss under different name.